AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones. The therapy is undergoing clinical development for patients suffering from...

Kite, a Gilead Company ,  announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell...

Sun Pharmaceutical Industries Limited had announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1...